BIM
LXRX icon

BlackRock Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlackRock Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.15M Sell
155,257
-40
-0% -$642 ﹤0.01% 2176
2016
Q3 		$2.81M Sell
155,297
-418
-0.3% -$6.73K ﹤0.01% 1896
2016
Q2 		$2.23M Buy
155,715
+8,712
+6% +$118K ﹤0.01% 2011
2016
Q1 		$1.76M Buy
147,003
+901
+0.6% +$9.45K ﹤0.01% 2089
2015
Q4 		$1.95M Buy
146,102
+1,439
+1% +$17.7K ﹤0.01% 2101
2015
Q3 		$1.55M Buy
144,663
+253
+0.2% +$2.76K ﹤0.01% 2260
2015
Q2 		$1.16M Buy
144,410
+46,288
+47% +$340K ﹤0.01% 2658
2015
Q1 		$649K Buy
98,122
+1,923
+2% +$13.1K ﹤0.01% 2815
2014
Q4 		$613K Buy
96,199
+4,159
+5% +$33.5K ﹤0.01% 2887
2014
Q3 		$908K Buy
92,040
+983
+1% +$10.5K ﹤0.01% 2592
2014
Q2 		$1.03M Sell
91,057
-1,069
-1% -$11.5K ﹤0.01% 2586
2014
Q1 		$1.12M Buy
92,126
+646
+0.7% +$8.26K ﹤0.01% 2432
2013
Q4 		$1.15M Sell
91,480
-1,696
-2% -$27K ﹤0.01% 2411
2013
Q3 		$1.55M Buy
93,176
+5,421
+6% +$90.9K ﹤0.01% 2133
2013
Q2 		$1.33M Buy
+87,755
New +$1.33M ﹤0.01% 2168

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's LXRX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 0.03% in Q4 2016, selling an estimated $642 and leaving 155,257 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

BlackRock Investment Management first reported a position in LXRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.81M in Q3 2016. 145 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

  • BlackRock Investment Management held 155,257 shares of Lexicon Pharmaceuticals worth $2.15M as of Q4 2016.
  • BlackRock Investment Management sold 40 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $642.
  • Lexicon Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2176 holding.
  • BlackRock Investment Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Lexicon Pharmaceuticals position peaked at $2.81M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.